Roberts J A, Thomson N C
Clin Allergy. 1985 Jul;15(4):377-81. doi: 10.1111/j.1365-2222.1985.tb03006.x.
In a group of atopic adult asthmatic patients the effects of two new inhaled antiasthmatic drugs, nedocromil sodium and minocromil were studied in two independent randomized double-blind trials to assess their efficacy in preventing exercise-induced asthma (EIA). Exercise testing consisted of steady state running on an inclined treadmill. Neither drug administered 30 min before exercise significantly altered baseline FEV1. Nedocromil sodium (2 and 4 mg) pre-treatment in nine patients and minocromil (4 mg) in eight patients gave significant protection (P less than 0.001) compared to placebo as assessed by the reduction in the maximum percentage fall in FEV1. There was no significant difference in the inhibitory effect of the two doses of nedocromil sodium. These results indicate that both nedocromil sodium and minocromil can attenuate EIA.
在一组特应性成年哮喘患者中，在两项独立的随机双盲试验中研究了两种新型吸入性抗哮喘药物——奈多罗米钠和米诺克罗米，以评估它们预防运动诱发性哮喘（EIA）的疗效。运动测试包括在倾斜的跑步机上进行稳态跑步。运动前30分钟给予的这两种药物均未显著改变基线第一秒用力呼气量（FEV1）。与安慰剂相比，9例患者接受奈多罗米钠（2毫克和4毫克）预处理以及8例患者接受米诺克罗米（4毫克）预处理，通过FEV1最大下降百分比的降低评估，均提供了显著的保护作用（P小于0.001）。两种剂量的奈多罗米钠的抑制效果无显著差异。这些结果表明，奈多罗米钠和米诺克罗米均可减轻运动诱发性哮喘。
